Intellipharmaceutics

157 articles with Intellipharmaceutics

• IntelliPharmaCeutics To Present At Dawson James Securities Growth Stock Conference

  10/9/2015

• IntelliPharmaCeutics Announces Third Quarter 2015 Results

  10/9/2015

• IntelliPharmaCeutics Updates Status Of Tentative Approvals Of Generic Focalin XR

  8/5/2015

• IntelliPharmaCeutics Announces Second Quarter 2015 Results

  7/13/2015

• IntelliPharmaCeutics Updates Status Of Tentative Approvals Of Generic Focalin XR

  7/9/2015

• IntelliPharmaCeutics Updates Status Of Tentative Approvals Of Generic Focalin XR

  6/19/2015

• IntelliPharmaCeutics Buys Property That Houses R&D & Office in Toronto, Ontario

  5/26/2015

• FDA Grants Fast Track Designation For IntelliPharmaCeutics Rexista Oxycodone XR Incorporating PODRAS Technology

  5/26/2015

• IntelliPharmaCeutics Intends To Accelerate Its Rexista(TM) Oxycodone XR Development Program On The Basis Of Positive Feedback From The FDA

  5/21/2015

• IntelliPharmaCeutics Reports Director Election Results

  4/22/2015

• IntelliPharmaCeutics Announces First Quarter 2015 Results

  4/16/2015

• IntelliPharmaCeutics Reports Positive Topline Data Results From A Series Of Phase I Clinical Trials Of Its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, And Files An IND For Rexista(TM) Oxycodone XR

  3/30/2015

• IntelliPharmaCeutics Announces 2014 Year End Results With A 48% Reduction In Operating Loss

  2/23/2015

• IntelliPharmaCeutics Reports The Signing Of An Exclusive Licensing And Manufacturing Agreement With TEVA Pharmaceuticals USA For An Extended Release Oral Drug Product Candidate

  2/2/2015

• IntelliPharmaCeutics Notes Launch Of 5mg Strength Of Focalin XR(R) Generic By Teva Pharmaceutical Industries Limited

  11/20/2014

• IntelliPharmaCeutics Reports That The FDA Has Given Its Toronto Manufacturing Facility An "Acceptable" Classification

  10/27/2014

• IntelliPharmaCeutics Reports Positive Results From A Series Of Phase I Clinical Trials Of Regabatin™ XR (Pregabalin Extended-Release)

  10/23/2014

• IntelliPharmaCeutics Announces Third Quarter 2014 Results

  10/16/2014

• IntelliPharmaCeutics Announces Resignation Of Chief Financial Officer

  10/1/2014

• IntelliPharmaCeutics Augments Its Rexista™ Oxycodone Development Program With Novel Overdose Deterrence Technology

  8/29/2014